ABSTRACT
The convenience and flexibility of antidiabetic regimens is known to positively impact treatment compliance. 4 For example, elderly patients, particularly those with some degree of cognitive dysfunction, are likely to experience difficulties in adhering to high-complexity regimens, involving frequent dosing, regular blood glucose monitoring, or meal planning. 4 It becomes increasingly clear, that simplified antidiabetic regimens that reduce dosing frequency, minimize requirements for blood glucose testing and are not meal-dependent, can prove to be particularly beneficial for specific subgroups of difficult-to-treat patients. 4 Of course, it is important to highlight that the safest and most effective way to manage 41 The clinical implications of the latter observation remain unresolved. to levels similar to those of healthy adults.
GLUCAGON-LIKE PEPTIDE 1 ANALOGS VERSUS ORAL DIPEPTIDYL PEPTIDASE 4 INHIBITORS
The differential characteristics of these two types of incretin-based treatments are schematically presented in Table 2 .
CLINICAL EFFICACY OF DAILY (SHORT-ACTING) GLUCAGON-LIKE PEPTIDE 1 ANALOGS
Exenatide: a Twice-Daily Glucagon-like
Peptide 1 Mimetic
Exenatide is a subcutaneously injected incretin mimetic, which needs to be preprandially After subcutaneous administration, exenatide is rapidly absorbed, reaching peak concentrations in approximately 2 hours. 45 As it is primarily cleared through the kidneys by glomerular filtration, the plasma half-life of subcutaneously administered exenatide is 2-3 hours, which is prohibitive for once-daily dosing. In LEAD-1, liraglutide added to glimepiride was well tolerated and provided improved glycemic control and favorable weight profile, compared with adding rosiglitazone to glimepiride. In LEAD-2, liraglutide induced similar glycemic control, reduced bodyweight, and lowered the incidence of hypoglycemia, compared with glimepiride, when they were both added to pre-existing metformin treatment. In LEAD-3, liraglutide proved to be both safe and effective as initial pharmacological therapy for T2DM, and led to greater reductions in HbA 1c , weight, hypoglycemia, and blood pressure than glimepiride monotherapy. In LEAD-4, liraglutide combined with metformin and rosiglitazone proved to be a well tolerated combination therapy for T2DM, and provided significant improvement in glycemic control. In LEAD-5, the strategy of adding liraglutide to combined treatment with glimepiride and metformin proved to be non-inferior to adding basal insulin glargine in terms of HbA 1c reduction. In LEAD-6 head-to-head study of liraglutide once daily versus exenatide twice daily (as add-on to metformin and/or sulfonylurea therapy), mean HbA 1c reduction was significantly greater with liraglutide treatment than with exenatide. 
Exenatide Long-Acting Release Formulation
Exenatide has been developed by Amylin were comparatively higher among exenatide LARtreated patients as opposed to exenatide twicedaily-treated patients. 79 It cannot be excluded that high titers of such antibodies may be associated with diminished therapeutic efficacy.
SAFETY ISSUES AND OVERALL CONCERNS ASSOCIATED WITH INCRETIN-BASED THERAPY
In early preclinical studies in rodents, long- 
